A recent trial shows that combination of two drugs could improve health of patients with cystic fibrosis. It increases the life expectancy of patients.
Cystic fibrosis is the most common fatal genetic disease. It directly affects lungs, pancreas, liver and kidney. Since last several decades, health researchers have been trying hard to find a cure but in vain. The symptoms of cystic fibrosis completely depend on the severity of the disease. Mostly people suffer from numerous issues of digestive system.
As per the report of World Health Organization, every year more than 10,000 people born with cystic fibrosis.
Presently, there are numerous drugs available in the market that can lessen the symptoms the disease. They are aimed to decrease the blockage of lungs and digestive system. However, the newly developed treatment can alter the genetic defect of the disease.
Researchers from Queen’s University carried out a trial on two drugs. Around 1,108 cystic fibrosis patients participated in the trial. They were requested to take two drugs (lumacaftor and invacaftor) for four weeks. The outcome of the trial reveals that combination of two drugs can fight against the disease. It targets and reduces number of “pulmonary exacerbations”.
Stuart Elborn, researcher at Queen University, remarks on the result of trial. He states that it is certainly a remarkable and effective drug for the disease.
The study is printed in detail in the New Journal of Medicine.